Abcam, ab241879, Human CD105 Antibody Pair - BSA and Azide free

Size: 10 x 96Tests
Human CD105 Antibody Pair - BSA and Azide free is a kit containing recombinant capture and detector antibodies in a carrier-free formulation for the measurement of Human CD105.
Key facts
Reacts with:Human,
Assay type:ELISA set,
Range:31.25 - 2000 pg/mL,
Assay Platform:Reagents

Product details:
The Antibody Pair can be used to quantify Human CD105. BSA and Azide free antibody pairs include unconjugated capture and detector antibodies suitable for sandwich ELISAs. The antibodies are provided at an approximate concentration of 1 mg/ml as measured by the protein A280 method. The recommended antibody orientation is based on internal optimization for ELISA-based assays. Antibody orientation is assay dependent and needs to be optimized for each assay type. Both capture and detector antibodies are rabbit monoclonal antibodies delivering consistent, specific, and sensitive results.
For additional information on the performance of the antibody pair, see the equivalent SimpleStep ELISA® Kit (
ab217773
), which uses the same antibodies. However, due to differences in their formulation, this antibody pair cannot be used with the consumables provided with our SimpleStep ELISA Kits. Please note that the range provided for the pairs is only an estimation based on the performance of the related product using the same antibody pair. Performance of the antibody pair will depend on the specific characteristics of your assay. We guarantee the product works in sandwich ELISA, but we do not guarantee the sensitivity or dynamic range of the antibody pair in your assay.
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with <1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
The pair can be used in variety of assays and platforms including but not limited to:
Sandwich ELISA
FRET/TR-FRET/HTRF
Meso Scale Discovery
Bead-based assays
AlphaLISA
/AlphaScreen
DELFIA
immunoassays
and Single Molecule Counting (SMC™) immunoassays
Multiplex
Our antibody pairs are supplied in a carrier-free format that is conjugation-ready:
Buffer free of BSA, sodium azide, and glycerol for higher conjugation efficiency.
Concentration of ~1 mg/ml as measured by the protein A280 method.
We can label antibodies for you: get in touch today to discuss how we can help accelerate your assay development with custom conjugation services.
Pairs are screened in biological samples, including plasma and serum, to ensure specificity in complex samples.
Please note:
The recommended antibody orientation is based on internal optimization in sandwich ELISA. Antibody orientation is assay dependent and needs to be optimized for each assay type.
The range provided for this antibody pair is based on initial sandwich ELISA validation data using recombinant protein. Performance and range of the antibody pair will depend on the specific characteristics of your assay, including standard protein selection.
We guarantee the product works in sandwich ELISA, but we do not guarantee the sensitivity or dynamic range of the antibodies in other assays.
Antibody properties:
Capture antibody:
recombinant rabbit monoclonal (unconjugated) – 100 µg
Detector antibody:
recombinant rabbit monoclonal (unconjugated) - 100 µg
Concentration
: ~1 mg/ml
Storage buffer:
100% PBS
Liquid
Isotype:
Recombinant monoclonal antibodies offer several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free production
Meso Scale Discovery and MSD are registered trademarks of Meso Scale Diagnostics, LLC.
AlphaLISA, AlphaScreen, and DELFIA are registered trademarks of PerkinElmer, Inc.
Simoa is a registered trademark of Quanterix, Inc.
SMC is a registered trademark of Merck KGaA, Darmstadt, Germany.

Properties and Storage Information:
Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-+4°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
CD105 also known as endoglin or the CD105 marker is a transmembrane glycoprotein with a molecular weight of approximately 180 kDa. It is a component of the TGF-beta receptor complex and exists in endothelial cells where it is abundantly expressed. Expression of CD105 is higher in proliferating cells particularly in the vasculature. You can also find it in tissues involved in the formation and remodeling of blood vessels such as during angiogenesis.
Biological function summary
Endoglin functions in the regulation of angiogenesis and vascular remodeling. It plays a significant role in mediating cellular responses to TGF-beta signaling influencing endothelial cell proliferation and migration. While not part of a larger structural complex endoglin interacts with receptors and signaling molecules important for vascular development and repair processes. This involvement aids in maintaining endothelial integrity and function under various physiological conditions.
Pathways
CD105 participates in the TGF-beta signaling and angiogenesis pathways. In these pathways it acts in conjunction with other proteins like TGF-beta receptors which play roles in cell differentiation proliferation and apoptosis. The interaction between CD105 and TGF-beta signaling regulates numerous cellular mechanisms impacting angiogenesis and cellular responses to environmental changes.
CD105 has links to hereditary hemorrhagic telangiectasia (HHT) and certain cancers. In HHT mutations in the endoglin gene alter vascular structure leading to the formation of abnormal blood vessels. Oncologically overexpression of CD105 is present in tumor angiogenesis aiding in the progression of certain cancers. Other proteins like VEGF and TGF-beta closely interact with endoglin influencing disease progression and presenting potential targets for therapeutic intervention.